A Pharmacogenomics‐Guided Antihypertensive Strategy for Blood Pressure Reduction in Rural China: A Cluster‐Randomized Controlled Trial
Health Care Science · 2026-08 · 5 (4) · 353-363
DOI: 10.1002/hcs2.70084 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Health Care Science, online erschienen am 10.06.2026. Verfasst von Wangjun Qin und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy China-Japan Friendship Hospital Beijing China. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Basic Research Program of China.
Abstract (Originalsprache)
Background
Although pharmacogenomics can effectively guide antihypertensive treatment, relevant evidence from low‑resource primary care settings is lacking. The aim of this study is to evaluate a pharmacogenomic‑guided antihypertensive strategy in real‑world, low‑resource primary care settings.
Methods
We randomly assigned 94 villages (in 1:1:1 ratio, with stratification by villages) to receive a multifaceted intervention that included follow‐up, health education, and medication adjustment guided by pharmacogenomics (treatment) or physician's experience (control), or routine care (observation) over 4 weeks. The primary outcome was the proportion of patients with controlled blood pressure after 4 weeks of treatment. Generalized linear, linear mixed‐effect regression, and sensitivity analysis were conducted to assess the difference among groups. The intracluster correlation coefficient was calculated to assess the heterogeneity with cluster.
Results
This study included 1031 hypertensive patients from 90 villages of Dajie and Jiuzhi towns in Daming County from May 10 to December 31, 2022. Overall, 79 loci on 39 antihypertensive‐related genes were tested for patients in the treatment group. After 4 weeks of treatment, 371 of 377 (98.4%) patients in the treatment group, 256 of 345 (74.2%) patients in the control group, and 232 of 309 (75.1%) patients in the observation group had their blood pressure under control. The between‐group net differences were 24.2% (95% confidence interval [CI]: 19.4%–29.0%) and 23.3% (95% CI: 18.3%–28.3%) for the treatment versus control groups and treatment versus observation groups, respectively. After 4 weeks of treatment, the proportion of patients with overall incident adverse events was no different among the three groups (all p > 0.05), and no serious adverse events or deaths related to antihypertensive treatment were reported during the study period.
Conclusions
A pharmacogenomic‐guided antihypertensive strategy can significantly enhance blood pressure control while maintaining a similar safety level compared to an experience‐guided antihypertensive strategy in low‐resource, primary care settings.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy China-Japan Friendship Hospital Beijing China.
- Research Department II China Development Research Foundation Beijing China.
- Department of Pharmacy Beijing Chao-Yang Hospital Beijing China.
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Clinical Research Design Division, Clinical Research Center, Sun Yat-Sen Memorial Hospital Sun Yat-Sen Univers…
- Department of Primary Care and Public Health Imperial College London London UK.
- General Office, Dajie Township Health Center Handan China.
ORCID-Profile: Azeem Majeed, Xianbo Zuo, Yue Qiu, Jiantuo Yu, Lihong Liu
Förderung
- National Basic Research Program of China
Zitieren
APA
Qin, W., Yu, M., Zhu, Y., Lin, Q., Yin, L., Liu, G., Wang, Y., Lu, G., Liu, X., Li, P., Kong, X., Zhao, L., Tang, K., Jin, J., Xiong, Y., Zhao, Y., Yan, Y., Li, B., Majeed, A., …, & Liu, L. (2026). A Pharmacogenomics‐Guided Antihypertensive Strategy for Blood Pressure Reduction in Rural China: A Cluster‐Randomized Controlled Trial. Health Care Science, 5(4), 353-363. https://doi.org/10.1002/hcs2.70084
Vancouver
Qin W, Yu M, Zhu Y, Lin Q, Yin L, Liu G, et al. A Pharmacogenomics‐Guided Antihypertensive Strategy for Blood Pressure Reduction in Rural China: A Cluster‐Randomized Controlled Trial. Health Care Science. 2026;5(4):353-363. doi:10.1002/hcs2.70084
BibTeX
@article{Qin2026,
author = {Qin, Wangjun and Yu, Mengke and Zhu, Ying and Lin, Queran and Yin, Limei and Liu, Guisheng and Wang, Yaping and Lu, Guangqiang and Liu, Xiaofei and Li, Pengmei and Kong, Xudong and Zhao, Li and Tang, Kun and Jin, Jiangli and Xiong, Yu and Zhao, Yingnan and Yan, Yan and Li, Bo and Majeed, Azeem and Zuo, Xianbo and Qiu, Yue and Yu, Jiantuo and Liu, Lihong},
title = {A Pharmacogenomics‐Guided Antihypertensive Strategy for Blood Pressure Reduction in Rural China: A Cluster‐Randomized Controlled Trial},
journal = {Health Care Science},
year = {2026},
volume = {5},
number = {4},
pages = {353--363},
doi = {10.1002/hcs2.70084}
}
EUVIMED